You are here

Our science / Clinical Trials / Find a Trial / NCT01224626

Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)

Back to Search Print Save as PDF Bookmark Trial

NCT01224626

Last updated on October 4, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Vancomycin Resistance Enterococcus Faecium
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0+
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject to whom Zyvox (linezolid) was administered.

- Infected subject with Vancomycin resistance Enterococcus faecium.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Infected subject with MRSA and other organism.

NCT01224626
Pfizer
Completed
Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Vancomycin Resistance Enterococcus Faecium
Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)
NCT01224626
All Genders
Gram-Positive Bacterial Infections, Staphylococcus Infections, Vancomycin Resistance, Methicillin Resistance
Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
NCT00079976
All Genders
Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)
Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)(Regulatory Post Marketing Commitment Plan)
To collect the efficacy and safety information in subjects who have been treated with Zyvox (linezolid) for vancomycin resistance Enterococcus faecium infection for their appropriate use in daily practice.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
The patients who are prescribed to Zyvox (linezolid).
Vancomycin Resistance Enterococcus Faecium
Drug: Zyvox (linezolid)
Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.
Other Name: linezolid, Zyvox
Zyvox (linezolid)
Patients who have been treated with Zyvox (linezolid).
Intervention: Drug: Zyvox (linezolid)
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
41
April 2011
April 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject to whom Zyvox (linezolid) was administered.
  • Infected subject with Vancomycin resistance Enterococcus faecium.

Exclusion Criteria:

  • Infected subject with MRSA and other organism.
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01224626
A5951139
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
May 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now